

# ITUS Corp

02:26 31 Jan 2015

## ITUS fiscal 2014 revenue soars 840% on strong execution

ITUS (OTCQB:ITUS) posted a gigantic 840 percent year-over-year increase in revenues in 2014, according to the patent enforcer's annual report filed with the SEC late Thursday.

For the fiscal year ending October 31, it generated revenue of \$3.67 million, up 840 percent from fiscal 2013. Operating costs also declined 25 percent to \$2.38 million.

"It is rare that a company is able to achieve exponential revenue growth, while simultaneously decreasing its operating costs," said president and chief executive officer, Robert Berman.

"Our execution in fiscal 2014 has put the company in a much stronger financial condition, and opens up new opportunities as we move forward."

The company said the latest results do not even include the \$9 million received from AU Optronics Corp, under a settlement announced in December.

ITUS, which acquires, enforces and makes money from patents, currently has 10 patent portfolios in areas such as encrypted cellular communications, key-based web conferencing encryption and other fields.

Its recently announced settlement with AU Optronics resolved a contract dispute between the two parties stemming from two development and license agreements signed back in May 2011. ITUS terminated these arrangements in January 2013, citing "numerous alleged material and continual breaches" by AU Optronics. ITUS then filed a lawsuit claiming breach of contract and other charges against AU, and a trial, which has since been dismissed, began on November 10, 2014.

In November, the company also inked its 30th settlement and/or license agreement for its J-Channel window frame construction technology patent.

In fiscal 2014, ITUS recorded revenue from patent assertions of \$2.48 million, from 27 license agreements in connections with its J-Channel and key based web conferencing patent portfolios. This compares with \$389,000 posted in the previous fiscal year, from four license agreements.

On a per share basis, the company also narrowed its net loss from 5 cents to 4 cents, while shareholders' equity increased to \$4.0 million, up \$7.3 million from year-end 2013.

### Share Information

**Code:** ITUS

**Listing:** NASDAQ

**Sector:** Pharma & Biotech

**Website:** [www.ituscorp.com](http://www.ituscorp.com)

### Company Synopsis:

*ITUS Corporation is a Nasdaq listed company (Nasdaq: ITUS) that is using the power of the immune system to diagnose cancer. Cchek, its early cancer detection platform, measures subtle changes which occur in the immune system at early tumor formation, and has been validated to work with 15 cancer types including Lung, Breast, Colon, Prostate, Ovarian, Pancreatic, Thyroid, and others.*

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.